Signaling pathways and therapeutic interventions in gastric cancer
Gastric cancer (GC) ranks fifth in global cancer diagnosis and fourth in cancer-related death.
Despite tremendous progress in diagnosis and therapeutic strategies and significant …
Despite tremendous progress in diagnosis and therapeutic strategies and significant …
Targeting gastric cancer stem cells to enhance treatment response
X Rao, C Zhang, H Luo, J Zhang, Z Zhuang, Z Liang… - Cells, 2022 - mdpi.com
Gastric cancer (GC) was the fourth deadliest cancer in the world in 2020, and about 770,000
people died from GC that year. The death of patients with GC is mainly caused by the …
people died from GC that year. The death of patients with GC is mainly caused by the …
The origin of gastric cancer stem cells and their effects on gastric cancer: Novel therapeutic targets for gastric cancer
Y Yang, WJ Meng, ZQ Wang - Frontiers in Oncology, 2022 - frontiersin.org
Gastric cancer (GC) is one of the most prevalent malignancies and the most common causes
of cancer-related mortality worldwide. Furthermore, the prognosis of advanced GC remains …
of cancer-related mortality worldwide. Furthermore, the prognosis of advanced GC remains …
Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy
J Zhu, T Wu, Q Lin - Molecular Biology Reports, 2023 - Springer
The transcriptional co-activators Yes-associated protein (YAP) and PDZ-binding domain
(TAZ) are the known downstream effectors of the Hippo kinase cascade. YAP/TAZ have …
(TAZ) are the known downstream effectors of the Hippo kinase cascade. YAP/TAZ have …